In a strategic move to enhance our product development capabilities, Precision NeuroMed has successfully acquired a cutting-edge Molecular Flow Simulations, a 510(k) cleared software solution from Therataxis. This acquisition marks a significant milestone for the company, allowing us to accelerate our research and development efforts.
The Molecular Flow Simulations is designed as a planning system for pre- and intra-operative planning of stereotactic or image-guided surgeries. MFS uses MR-DTI and T2-weighter MR images with brain anatomy to display likely volumes of fluid distribution. This technology will form the foundation of Precision NeuroMed’s Treatment Planning Software, designed to optimize convection enhanced drug delivery in a consistent and reproducible manner. The advanced capabilities of MFS will enable Precision NeuroMed to enhance testing processes, improve product performance, and drive innovation across multiple therapeutic domains.